X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Glenmark Pharma with Cipla - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs CIPLA - Comparison Results

GLENMARK PHARMA    Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GLENMARK PHARMA CIPLA GLENMARK PHARMA/
CIPLA
 
P/E (TTM) x 25.3 40.6 62.2% View Chart
P/BV x 4.0 3.7 106.0% View Chart
Dividend Yield % 0.3 0.5 67.2%  

Financials

 GLENMARK PHARMA   CIPLA
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-17
CIPLA
Mar-18
GLENMARK PHARMA/
CIPLA
5-Yr Chart
Click to enlarge
High Rs993663 149.8%   
Low Rs729479 152.3%   
Sales per share (Unadj.) Rs325.5189.0 172.2%  
Earnings per share (Unadj.) Rs39.317.6 223.3%  
Cash flow per share (Unadj.) Rs48.734.0 143.0%  
Dividends per share (Unadj.) Rs2.003.00 66.7%  
Dividend yield (eoy) %0.20.5 44.2%  
Book value per share (Unadj.) Rs159.2176.7 90.1%  
Shares outstanding (eoy) m282.17805.12 35.0%   
Bonus/Rights/Conversions ESOPESOP-  
Price / Sales ratio x2.63.0 87.6%   
Avg P/E ratio x21.932.5 67.5%  
P/CF ratio (eoy) x17.716.8 105.4%  
Price / Book Value ratio x5.43.2 167.4%  
Dividend payout %5.117.1 29.9%   
Avg Mkt Cap Rs m242,991459,724 52.9%   
No. of employees `00013.023.6 54.9%   
Total wages/salary Rs m16,40826,901 61.0%   
Avg. sales/employee Rs Th7,083.96,446.1 109.9%   
Avg. wages/employee Rs Th1,265.41,139.4 111.1%   
Avg. net profit/employee Rs Th855.1600.0 142.5%   
INCOME DATA
Net Sales Rs m91,857152,193 60.4%  
Other income Rs m3743,577 10.4%   
Total revenues Rs m92,230155,769 59.2%   
Gross profit Rs m20,36728,264 72.1%  
Depreciation Rs m2,64413,228 20.0%   
Interest Rs m2,3731,142 207.8%   
Profit before tax Rs m15,72417,470 90.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-28 0.0%   
Extraordinary Inc (Exp) Rs m-810-775 104.4%   
Tax Rs m3,8272,501 153.0%   
Profit after tax Rs m11,08814,166 78.3%  
Gross profit margin %22.218.6 119.4%  
Effective tax rate %24.314.3 170.0%   
Net profit margin %12.19.3 129.7%  
BALANCE SHEET DATA
Current assets Rs m68,746108,141 63.6%   
Current liabilities Rs m27,02738,322 70.5%   
Net working cap to sales %45.445.9 99.0%  
Current ratio x2.52.8 90.1%  
Inventory Days Days8597 87.6%  
Debtors Days Days9674 128.4%  
Net fixed assets Rs m24,132109,411 22.1%   
Share capital Rs m2821,610 17.5%   
"Free" reserves Rs m44,643140,682 31.7%   
Net worth Rs m44,925142,292 31.6%   
Long term debt Rs m45,36336,621 123.9%   
Total assets Rs m117,639228,606 51.5%  
Interest coverage x7.616.3 46.8%   
Debt to equity ratio x1.00.3 392.3%  
Sales to assets ratio x0.80.7 117.3%   
Return on assets %11.46.7 170.9%  
Return on equity %24.710.0 247.9%  
Return on capital %19.110.0 192.4%  
Exports to sales %032.8 0.0%   
Imports to sales %00-   
Exports (fob) Rs mNA49,883 0.0%   
Imports (cif) Rs mNANA-   
Fx inflow Rs m56,15251,691 108.6%   
Fx outflow Rs m8,08421,033 38.4%   
Net fx Rs m48,06830,658 156.8%   
CASH FLOW
From Operations Rs m6,57414,628 44.9%  
From Investments Rs m-7,124-8,540 83.4%  
From Financial Activity Rs m5,432-3,855 -140.9%  
Net Cashflow Rs m1,9922,431 82.0%  

Share Holding

Indian Promoters % 48.3 16.0 301.9%  
Foreign collaborators % 0.0 20.8 -  
Indian inst/Mut Fund % 6.9 12.2 56.6%  
FIIs % 34.4 23.7 145.1%  
ADR/GDR % 0.0 1.1 -  
Free float % 10.5 26.2 40.1%  
Shareholders   56,727 161,166 35.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GLENMARK PHARMA With:   SUVEN LIFE  SUN PHARMA  PFIZER  TTK HEALTHCARE  SHASUN PHARMA  

Compare GLENMARK PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps Over 275 Points; Realty and Banking Stocks Witness Selling(Closing)

After trading on a volatile note throughout the day, share markets in India witnessed selling pressure during the closing hours and ended the day in red.

Related Views on News

GLENMARK PHARMA Announces Quarterly Results (1QFY19); Net Profit Down 30.1% (Quarterly Result Update)

Aug 13, 2018 | Updated on Aug 13, 2018

For the quarter ended June 2018, GLENMARK PHARMA has posted a net profit of Rs 2 bn (down 30.1% YoY). Sales on the other hand came in at Rs 22 bn (down 8.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

CIPLA Announces Quarterly Results (1QFY19); Net Profit Up 4.7% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, CIPLA has posted a net profit of Rs 4 bn (up 4.7% YoY). Sales on the other hand came in at Rs 39 bn (up 11.7% YoY). Read on for a complete analysis of CIPLA's quarterly results.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Cipla: Extraordinary Income Boosts Net Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

Proceeds from the sale of the South African animal business bolstered Cipla's net profits for the quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Sep 21, 2018 (Close)

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA 5-YR ANALYSIS

COMPARE GLENMARK PHARMA WITH

MARKET STATS